Xellia Pharmaceuticals announced Monday it has acquired Fresenius Kabi’s manufacturing plant in Raleigh. The facility is the Denmark-based company’s first in the United States.

The acquisition includes an ongoing manufacturing agreement between Xellia and Fresenius Kabi. Xellia will continue to manufacture products, such as medicines and transfusion technologies, at the site for Fresenius Kabi. Financial details of the acquisition were not disclosed.

Headquartered in Copenhagen, Xellia Pharmaceuticals…